Health X Platform Limited (formerly known as Sastasundar Ventures Limited) will engage with investors and analysts during a virtual meeting scheduled for June 12, 2026, at 4:00 P.M. IST. The company intends to discuss its performance and strategy to ensure stakeholders remain informed about its business operations.

The event will be conducted as a Group Conference via a virtual mode, requiring prior registration. Health X Platform noted that the schedule remains subject to change due to exigencies on the part of the analysts or investors.

Event Details

The company explicitly stated that only information already available in the public domain will be shared or discussed during the interaction. It further clarified that no unpublished price sensitive information will be disclosed during the session.

This disclosure was submitted to BSE Limited and National Stock Exchange of India Limited in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was signed by Pratap Singh, Company Secretary & Compliance Officer.

Health X Platform reported a consolidated net loss of ₹1.4 crore for the financial year ended March 31, 2026, narrowing significantly from a net loss of ₹133.5 crore in the previous year. The company's revenue from operations rose 20% to ₹1,305.9 crore in FY26, compared to ₹1,088.1 crore in FY25, primarily led by its Healthcare Network segment. The Board of Directors approved the audited standalone and consolidated financial results at its meeting held on May 30, 2026. The company filed an investor presentation with exchanges on June 1, 2026, detailing its strategic priorities and operational metrics.

Consolidated Financial Performance

The company's total comprehensive income for the year stood at ₹0.74 crore, a turnaround from the total comprehensive loss of ₹1,339.9 crore reported in FY25. For the quarter ended March 31, 2026, the company reported a net loss of ₹12.9 crore, compared to a net profit of ₹17.6 crore in the corresponding quarter of the previous year. Revenue from operations for the quarter increased to ₹378.1 crore from ₹281.9 crore in the same period last year. The statutory auditors, M/s JKVS & Co, provided an unmodified opinion on the standalone and consolidated audited financial results.

Segment and Operational Highlights

The Healthcare Network segment was the primary revenue driver, contributing ₹1,283.1 crore for the year, while the Financial Services segment reported revenue of ₹94.4 crore. The company, which changed its name from Sastasundar Ventures Limited during the year, operates as a Core Investment Company with a single reportable business segment within India. Exceptional items for the year totaled a loss of ₹1.1 crore, compared to a loss of ₹190.5 crore in the previous year. The company highlighted that working capital days improved to 18 days in Q4 FY26 from 23 days in Q4 FY25, representing a 31% year-over-year decrease.

Strategic Priorities and Capital Efficiency

The company outlined strategic priorities for the next five years, targeting a CAGR of 30%+ through customer acquisition, geographic penetration, and category expansion. It plans to integrate AI across the value chain for counselling and process automation. Capital efficiency metrics showed that net capital deployed in the Intellectual Property Rights (IPR) of the business stood at ₹119 crore. The company operates 62,000 retail pharmacies and utilizes 50,000+ SKUs from 700+ vendors, with a purchase return rate of less than 1%.

Standalone Results and Governance

On a standalone basis, the company reported a net loss of ₹0.95 crore for FY26, widening from a net loss of ₹0.71 crore in FY25. Total income decreased to ₹0.76 crore from ₹1.20 crore in the previous year. The Board re-appointed M/s. Priya Gupta & Co., Chartered Accountants, as the Internal Auditor for the financial year 2026-27.

Key Financial Metrics (Consolidated)